PTC Therapeutics
PTCTPTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.In September 2009, PTC entered into an agreement with R …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2024-2026
All insider trades at PTC Therapeutics
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 2/18/2026 | Sell | Pauwels, Eric | CHIEF BUSINESS OFFICER | $69.4 | $209,398 |
| 2/18/2026 | Sell | Almstead, Neil Gregory | CHIEF TECHNICAL OPS OFFICER | $69.4 | $216,472 |
| 2/18/2026 | Sell | Boulding, Mark Elliott | EXEC. VP AND CLO | $69.4 | $213,698 |
| 2/18/2026 | Sell | Golden, Lee Scott | EVP & CHIEF MEDICAL OFFICER | $69.4 | $172,290 |
| 2/18/2026 | Sell | Utter, Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | $69.4 | $172,984 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)